Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Summary

This is a prospective, multicenter, single arm, phase II trial in patients with ≥ 18 and \<65 years with poor-prognosis (IPI ≥ 2) and newly diagnosed ABC-DLBCL. Aim of the study is to assess the efficacy and the safety of R-CHOP in combination with ibrutinib for 6 cycles followed by ibrutinib maintenance for 18 months in ABC-DLBCL patients achieving at least a PR after the induction phase

Timeline

Start

2019-07-02

Primary completion

2024-07-30

Completion

2027-07

Drugs

Indications